Drugnews

Updated

Osteoporosis: Asian pipelines and global competitors

As of 2026-11-14, Asian osteoporosis participants include Celltrion, Samsung Bioepis and Henlius, each with a denosumab biosimilar. Their mechanism differs from the global comparators romosozumab and abaloparatide. This page distinguishes antiresorptive and bone-forming pathways and does not present biosimilars as novel mechanisms.

Bone resorption and bone formation

Selected injectable biologics and peptides, not a census of all osteoporosis medicines. Oncology bone-disease presentations are kept separate.

Asian companies

AssetCompanyMechanism / routeStageIndicationLatest verified recordSources
CT-P41 / STOBOCLO
Celltrion (South Korea)
Anti-RANKL; denosumab biosimilar
SC
Approved and launched in the US
High-fracture-risk osteoporosis and other labeled indications
US launch announcement: STOBOCLO references Prolia; the OSENVELT oncology presentation is distinct.
SB16 / OSPOMYV / OBODENCE
Samsung Bioepis (South Korea)
Anti-RANKL; denosumab biosimilar
SC
Approved in the US / EU
Osteoporosis and other labeled indications
Reported Phase 3 osteoporosis subgroup analyses; not a novel mechanism or new approval announcement.
HLX14 / BILDYOS
Henlius / Organon
Anti-RANKL; denosumab biosimilar
SC
Approved in North America / Europe; China application under review
Osteoporosis and other indications; BILDYOS presentation
The 2026 interim deck lists approval and filing status; its August cover date is used, not the November upload path.

Global comparators

AssetCompanyMechanism / routeStageIndicationLatest verified recordSources
denosumab / Prolia
Amgen
Anti-RANKL antibody; reference product
SC
Approved
Osteoporosis and other labeled indications
Q3 global sales were USD 632 million; the company noted multiple biosimilar launches globally.
romosozumab / EVENITY
Amgen / UCB
Anti-sclerostin antibody
SC
Approved
Postmenopausal osteoporosis at high fracture risk
Q3 filing reports global quarterly EVENITY sales of USD 751 million; a financial event is not new efficacy evidence.
abaloparatide / TYMLOS
Radius Health
PTHrP analog
SC
Approved in the US
High-fracture-risk postmenopausal women; increased bone density in men
DailyMed label updated on 08-11, including hypersensitivity warnings; this predates the page’s 90-day window.

Events in the last 90 days

2026-08-17 – 2026-11-14

Sources and downloads

  1. Celltrion US launch — 2025-07-08
  2. Samsung SB16 osteoporosis subgroup analysis — 2026-04-17
  3. Samsung SB16 approval listing — Undated
  4. Henlius interim presentation, pp. 25–26 — 2026-08
  5. Amgen Q3 2026 results — 2026-11-03
  6. TYMLOS label — 2026-08-11

Information cutoff 2026-11-14